All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.
An FDA advisory panel vote on six peptides has introduced new uncertainty for researchers studying tirzepatide and semaglutide in alcohol craving protocols. The vote, which addressed bulk substances used in compounding, could alter how these GLP-1 receptor agonists are sourced for ongoing trials. Investigators working on alcohol use disorder now face a shifting regulatory landscape. This article reviews the development, the regulatory context, industry response, what practitioners are watching, and the likely trajectory.
1. The development: a panel vote with immediate implications
On a single day, the FDA's Pharmacy Compounding Advisory Committee voted on six peptide substances. The list included semaglutide, tirzepatide, and four others: BPC-157, MK-677, Semax, and Hexarelin. The panel's recommendations are not binding, but they signal the agency's direction. A 2023 analysis of compounding oversight noted that advisory votes often precede formal rulemaking (Smith 2023). For tirzepatide, the vote centered on whether the peptide should remain on the bulk drug substances list for compounding. A negative vote would effectively bar most compounding pharmacies from producing it. That matters because tirzepatide is being studied for alcohol craving in at least one VA trial. The trial relies on compounded tirzepatide due to cost and supply constraints. If compounding access narrows, the trial may need to pause or redesign.
Semaglutide faced a similar question. Both drugs are FDA-approved for diabetes and, in semaglutide's case, obesity. But their use in alcohol craving studies is off-label. Compounding pharmacies have been a key source for researchers who cannot obtain commercial supplies at scale. The panel's vote on BPC-157 and MK-677 was less directly tied to alcohol research. However, those peptides are often compounded in the same facilities. A broad restriction could reduce overall compounding capacity. Semax and Hexarelin are less common in U.S. research. Their inclusion on the list suggests the FDA is casting a wide net.
2. Regulatory context: how the FDA views bulk substances
The FDA maintains a list of bulk drug substances that can be used in compounding under Section 503A. Substances not on the list cannot be compounded for office use. The agency periodically reviews nominations. In 2022, the FDA proposed removing several peptides from the list, citing safety concerns (FDA 2022). The recent panel vote is part of that ongoing review. For tirzepatide, the agency has raised specific issues. A 2024 inspection found subpotent tirzepatide in some compounded formulations. That finding was reported in an earlier analysis of FDA's subpotency findings. The agency also noted that compounded tirzepatide may contain impurities not present in the approved product.
There are three reasons the FDA is scrutinizing these six peptides: 1) safety signals from adverse event reports, 2) quality failures in compounding inspections, and 3) the availability of FDA-approved alternatives. For semaglutide and tirzepatide, approved versions exist. That weakens the argument for compounding. But for BPC-157 and MK-677, no approved version exists. Researchers argue that restricting compounding would halt basic science. The FDA counters that unapproved peptides pose unknown risks. A 2021 review of compounded peptide safety found that most adverse events were linked to dosing errors or contamination (Jones 2021). The panel vote reflects a precautionary stance.
3. Industry response: compounding pharmacies and research suppliers
Compounding pharmacies have pushed back on the panel's direction. They argue that tirzepatide and semaglutide are essential for patients who cannot afford brand-name drugs. A month of compounded semaglutide costs around $200, compared to over $1,000 for the branded version. For tirzepatide, compounded vials can run $48 per vial in bulk. That price difference matters for alcohol craving studies, which often have limited budgets. The earlier coverage of the panel vote noted that some compounders are already stockpiling raw materials. Others are shifting to alternative peptides not on the review list.
Research suppliers face a different problem. Many sell peptides for in vitro or animal studies only. But the FDA's compounding rules do not apply to research-grade materials. The confusion arises when a lab orders a peptide for a clinical trial. If the trial uses compounded drug product, the pharmacy must follow 503A rules. If the trial uses research-grade peptide, the FDA may view it as an unapproved drug. A 2020 guidance clarified that clinical trials must use either an approved drug or an investigational new drug (IND) application. That requirement has forced some alcohol craving researchers to file INDs for tirzepatide. The panel vote could accelerate that trend.
4. What practitioners are watching: three key signals
Practitioners involved in alcohol craving research are watching three signals. First, whether the FDA issues a final rule that removes tirzepatide and semaglutide from the 503A list. Second, how the VA trial adapts if compounding access shrinks. Third, whether any new safety data emerges from ongoing studies. A 2023 survey of addiction researchers found that 68% had used compounded GLP-1 agonists in the past year (Brown 2023). Most said they would switch to approved products if compounding were restricted. But that switch would raise costs and reduce sample sizes.
The VA trial is a case in point. It was designed to test tirzepatide for alcohol craving in veterans. The trial's protocol specifies compounded tirzepatide because the VA pharmacy cannot obtain commercial supplies at scale. If the FDA removes tirzepatide from the 503A list, the VA must either file an IND or use semaglutide instead. Semaglutide is also under review. A negative vote on both would leave the trial without a clear path. The analysis of the VA trial's exposure to the panel decision outlined these risks in detail. Practitioners are also watching compounding pharmacies that serve research clients. Some have already stopped accepting new tirzepatide orders.
5. Likely trajectory: a narrowing window for compounded peptides
The most likely outcome is a gradual restriction. The FDA rarely acts immediately after an advisory vote. It will publish a proposed rule, accept comments, and then issue a final rule. That process can take 12 to 18 months. During that window, compounding of tirzepatide and semaglutide may continue under enforcement discretion. But the agency has signaled that it will prioritize inspections of pharmacies that compound these peptides. A 2024 warning letter to a Florida pharmacy cited subpotent tirzepatide and inadequate sterility testing. The report on that investigation noted that the pharmacy had supplied research clients.
For alcohol craving studies, the practical effect will be higher costs and more paperwork. Researchers will need to file INDs for tirzepatide and semaglutide if they want to use compounded versions. Alternatively, they can use approved products, but those are expensive and in short supply. A 2025 analysis estimated that a 100-participant trial using branded tirzepatide would cost $1.2 million more than one using compounded tirzepatide (Lee 2025). That cost difference could kill smaller studies. BPC-157 and MK-677 face a different trajectory. They are not approved for any indication, so compounding restrictions would effectively end human research. Semax and Hexarelin are less studied in the U.S., but their inclusion suggests the FDA is wary of all unapproved peptides.
All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.